TABLE 2.
Adjusted and unadjusted hazard of breakthrough IFI among patients receiving posaconazole prophylaxisa
| Characteristic | Unadjusted HR (95% CI) | Adjusted HR (95% CI) |
|---|---|---|
| Tablet formulation | 1.1 (0.4–3.1) | 1.2 (0.4–3.4) |
| Nasogastric tube administration | 23.9 (4.6–83.4) | 34.1 (6.3–128.9) |
| Male sex | 2.0 (0.7–7.8) | 2.2 (0.7–8.6) |
| Antiviral therapy | 0.4 (0.1–1.1) | 0.4 (0.1–1.2) |
| Underlying diagnosis (cancer vs GVHD and other high-dose steroid use) | 1.5 (0.5–5.9) | |
| Antibiotic therapy | 0.9 (0.2–8.5) | |
| Proton pump inhibitors | 0.5 (0.2–1.4) | |
| Mucositis | 2.5 (0.6–7.5) | 4.6 (1.0–17.5) |
| Met NCCN criteria for prophylaxis | 1.3 (0.3–12.0) | |
| Posaconazole level taken during course | 1.0 (0.4–2.8) | |
| Age > 65 years | 2.6 (0.9–7.1) | 3.7 (1.2–12.1) |
| BMI > 30 (kg/m2) | 0.6 (0.2–1.9) |
a
Data are for 860 courses. GVHD, graft-versus-host disease; NCCN, National Comprehensive Cancer Network; BMI, body mass index.